Core Insights - Argenx SE – ADR (NASDAQ:ARGX) is recognized as a promising healthcare stock for 2026, particularly following the FDA's acceptance of a priority review for its drug Vyvgart [1][2] Group 1: FDA Review and Drug Indication - The FDA has granted priority review status for a supplemental biologics license application aimed at expanding Vyvgart's use for treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG) [2] - If the application is successful, it will broaden the patient population eligible for Vyvgart, potentially increasing its market reach [2] Group 2: Sales Momentum and Market Sentiment - William Blair has reiterated an Outperform rating on Argenx, citing strong sales momentum in the Vyvgart franchise, with sales exceeding expectations [3] - The positive sales trend is anticipated to continue through 2026 across indications in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [3] Group 3: Company Overview - Argenx SE is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers [4]

Dow Jones Leader Amgen Leads These Biotechs Heading Into O4 Earnings | Investor's Business DailyBREAKING: [Trump Names Warsh New Fed Chairman] --- Biotech stocks continue to outperform in the current stock market rally, as Dow Jones index component and industry giant Amgen (AMGN), alone with Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Argenx (ARGX) trade in or near buy zones. Fourth-quarter earnings season is kicking into full swing, which will spur stock mar ...

Argenx SE (NASDAQ:ARGX) ranks among the best high growth European stocks to buy. On January 12, William Blair maintained its Outperform rating on Argenx SE (NASDAQ:ARGX), citing robust sales growth in the company’s Vyvgart brand. The firm reports that Vyvgart sales stay ahead of expectations and demonstrate solid momentum, which it expects to last through 2026 across authorized applications in MG (myasthenia gravis) and CIDP. The firm also emphasized the potential of Argenx’s other clinical products, inc ...

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Stocks to Buy for Investment. On January 20, TheFly reported that Wells Fargo increased the price target on Argenx SE (NASDAQ:ARGX) from $1,264 to $1,317, keeping an Overweight rating on the shares. Wells Fargo Analysts Sees Potential in Argenx SE's Vyvgart, Increases PT To $1,317 Pixabay/Public Domain Derek Archila from Wells Fargo raised the price target on ARGX following its strong outlook on Argenx’s Vyvgart, according to TheFly. Archila has raised the ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, indicating a looming crisis in power supply as AI continues to grow [2][3] Investment Opportunity - A specific company is noted as a potential investment opportunity, possessing critical energy infrastructure assets that are essential for supporting the increasing energy needs of AI data centers [3][7] - This company is described as a "toll booth" operator in the AI energy boom, benefiting from the surge in demand for electricity driven by AI advancements [4][5] Market Position - The company is positioned at the forefront of America's energy strategy, owning significant nuclear energy infrastructure and being capable of executing large-scale projects across various energy sectors [7][8] - It is noted that this company is debt-free and has a substantial cash reserve, equating to nearly one-third of its market capitalization, which provides a strong financial foundation [8][10] Competitive Advantage - The company also holds a significant equity stake in another AI-related venture, offering investors indirect exposure to multiple growth opportunities in the AI sector without the associated high premiums [9][10] - The stock is described as undervalued, trading at less than 7 times earnings, which presents a compelling investment case compared to other firms in the energy and utility sectors [10][11] Industry Trends - The article discusses the broader trends of onshoring and tariffs under the Trump administration, which are expected to drive growth in U.S. LNG exports and benefit the company [6][14] - The influx of talent into the AI sector is noted, ensuring continuous innovation and advancements, which further supports the investment thesis in AI-related companies [12][13]

We came across a bullish thesis on argenx SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on ARGX. argenx SE's share was trading at $833.16 as of January 26th. ARGX’s trailing and forward P/E were 35.64 and 27.93 respectively according to Yahoo Finance. Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress Copyright: nexusplexus / 123RF Stock Photo argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of ...

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the ClearBridge Mid Cap Strategy reported underperformance versus the Russell Midcap Index, which returned 0.16% during the period, as narrow market leadership and sentiment-driven trading weighed on results. Weakness in information technology and real estate holdings pressured returns, while gains in select consumer ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies w ...

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]